Kolexia
Roubaud Guilhem Oncologie médicale
Roubaud Guilhem
Oncologie médicale
Institut Bergonié
Bordeaux, France
218 Activités
92 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs prostatiques résistantes à la castration Tumeurs de la vessie urinaire Carcinomes Métastase tumorale Tumeurs embryonnaires et germinales Carcinome transitionnel Récidive tumorale locale Néphrocarcinome

Collaborateurs

Voir plus
Sargos Paul
Sargos Paul
Institut Bergonié, Bordeaux, France
Flechon Aude
Flechon Aude
Centre Léon-Bérard, Lyon, France
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Fizazi Karim
Fizazi Karim
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Janssen
34 collaboration(s)
Dernière en 2023
Ipsen
21 collaboration(s)
Dernière en 2023
AstraZeneca
15 collaboration(s)
Dernière en 2023
Astellas
13 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (MacroGenics)   18 mars 2024
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.: ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Essai Clinique (Swiss Group for Clinical Cancer Research)   11 mars 2024
Analyse descriptive de la plus grande cohorte mondiale de patients atteints de CPRCm traités en accès précoce par [177Lu]Lu-PSMA-617
10e Journées Francophones de Médecine nucléaire - Biarritz   01 mars 2024
Traitement du cancer de la prostate métastatique : état de l’art
Bulletin de l'Academie nationale de medecine   29 février 2024
MAGNITUDE: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Essai Clinique (Janssen)   27 février 2024
STARTER: A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Essai Clinique (Centre Léon-Bérard)   20 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
KEYLYNK-010: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Essai Clinique (Merck & Co.)   31 janvier 2024